Adult Immunization

Anaphylaxis

Food Allergies

Seasonal Allergies

Allergy

Atrial Fibrillation

Cardiovascular Disease

Heart Failure

Hypertension

Lipid disorders

Cardiology

Clinical Technology

Atopic Dermatitis

Psoriasis

Rosacea

Dermatology

Adrenal Disorders

Diabetes

Thyroid Disorders 

Endocrinology 

C Difficile Infection

Celiac disease

GERD

Inflammatory Bowel Disease

Irritable Bowel Syndrome 

Gastroenterology

Hepatitis

MASLD/MASH

Hepatology

Coronavirus

HIV AIDS

Hepatitis C

Influenza

Pneumonia

Sexually transmitted infections

Infectious Disease

Chronic Kidney Disease

Nephrology

Alzheimer Disease/Dementia

Cerebrovascular Diseases

Dementia

Epilepsy

Headache

Mental Health

Migraine

Nervous System Diseases

Parkinson Disease

Sleep Disorders

Stroke

Neurology

Obesity Medicine

Fibromyalgia

Pain Management

Pediatric Immunization

Pediatrics

ADHD

Anxiety

Depression

Eating Disorders

PTSD

Panic Disorder  

Psychosis

Substance-related Disorders

Psychiatry 

Asthma

COPD

Cystic Fibrosis

Interstitial lung disease

Pulmonary hypertension

Respiratory Diseases

Pulmonology

Gout

Lupus

Osteoarthritis

Psoriatic arthritis

Rheumatoid Arthritis

Rheumatology

Breast Cancer

Cervical Cancer

Colorectal Cancer

Lung Cancer

Melanoma

Prostate Cancer

Renal Cancer

Skin cancer

Screening

Menopause

Osteoporosis

Pregnancy and Birth

Women's Health

News

All News

Editorial Podcasts

Practice Management

Video Interviews

Media

Around the Practice

Between the Lines

ConsultantLive

Frontline Insights

Institutional Insights

Primary View

Provider Toolkits

Screening Series

Conferences

Conference Coverage

Conference Listing

Product Theater Recaps

Resources

Interactive Posters

Product Profile

Publications

Subscribe

CE/CME

Patient Care Online offers clinical news and resources for primary care clinicians, focusing on disease states, guidelines, and trends to improve care.

About Us

Advertise

Contact Us

Editorial Board

Terms and Conditions

Privacy

Do Not Sell My Information

Patient Care Online – Primary Care News and Clinical Resources

Facebook

LinkedIn

Clinical Focus

Allergy & Immunology

Endocrinology

Men’s Health

Psychiatry

Women’s Health

Business Focus

Billing and Collections

Career Planning

Coding and Documentation

Concierge Medicine

Cybersecurity

EHRs

Investing

Patient Relations

Personal Finance

Remote Patient Monitoring

Staffing

Technology

Telehealth

Value-based Care

Spotlight

VMS and Menopause

Atopic Dermatitis Provider Toolkit

Adult Immunization Provider Toolkit

Dermatology Hot Topics

1rem

Authors

A 52-year-old man with a 29-year history of type 1 diabetes mellitus and mild diabetic retinopathy and nephropathy presents for a regular checkup.

Man With Abdominal Bruit of Unusual Origin

Revolutionizing Atopic Dermatitis (RAD) 2025

in Nashville, Tennessee, offers important updates for primary care physicians managing this common chronic condition. From long-term safety data on biologics like dupilumab and upadacitinib to new findings on atopic dermatitis (AD) during pregnancy, social determinants of disease, and treatment delays due to insurance barriers, this year's abstracts underscore the growing complexity of care for both pediatric and adult patients.

Above, find 10 medical abstract titles from RAD 2025 that are most relevant to frontline clinicians, including insights on comorbid asthma management, topical innovations, growth trends in children with AD, and real-world effectiveness data.

Preview of 10 new studies on managing atopic dermatitis, including biologics, treatment barriers, and innovative care strategies for clinicians.

Clinical Topics

New Data on Atopic Dermatitis for Frontline Clinicians

Roflumilast cream 0.15% (ZORYVE) has received a strong recommendation in the American Academy of Dermatology’s (AAD) focused guideline update for the management of mild to moderate atopic dermatitis (AD) in adults, according to a June 26 announcement from Arcutis Biotherapeutics.

 Among newly evaluated branded topical therapies, roflumilast 0.15% is the only agent to receive a strong recommendation, the company noted, reflecting its demonstrated ability to reduce pruritus and disease severity while maintaining a favorable safety and tolerability profile.

The nonsteroidal, topical phosphodiesterase-4 (PDE4) inhibitor is indicated for use in adults and children aged 6 years and older, offering clinicians a targeted treatment option suitable for sensitive and difficult-to-treat areas of the body.

The AAD’s focused update integrates newly FDA-approved topical and biologic therapies into existing guidelines to ensure clinicians have access to the most current, evidence-based recommendations for this chronic inflammatory condition.

 Roflumilast cream 0.15% joins tapinarof cream, lebrikizumab, and nemolizumab (with concomitant topical therapy) as 1 of 4 new agents included in the latest guidance.

“The AAD’s focused update highlights therapies that meet rigorous standards for efficacy, safety, and tolerability for adults living with AD,” Patrick Burnett, MD, PhD, chief medical officer at Arcutis, said in the statement. “The inclusion of [roflumilast 0.15%] in these recommendations validates what healthcare professionals have already experienced with [the therapy] in their practice – a next-generation, steroid-free topical that delivers meaningful improvement for people with AD.”

Roflumilast is the only FDA-approved branded topical PDE4 inhibitor indicated for AD, plaque psoriasis, and seborrheic dermatitis. The strong recommendation in adult AD underscores its relevance in current dermatologic care.

 “The AAD’s strong recommendation helps guide clinicians and patients toward treatments that deliver clinically meaningful improvements in disease severity while being safe and well tolerated for long-term use,” Arcutis noted in the announcement.

 [Roflumilast 0.15%] was also recently awarded the National Psoriasis Foundation’s Seal of Recognition, the first FDA-approved prescription product to earn the honor.

Efforts to expand the approved use of [roflumilast 0.15%] in pediatric populations are ongoing. The FDA is currently reviewing a supplemental New Drug Application for the use of roflumilast cream 0.05% in children aged 2 to 5 years with mild to moderate AD.

The application is supported by pivotal phase 3 trials (INTEGUMENT-PED), long-term extension data (INTEGUMENT-OLE), and pharmacokinetic studies. A Prescription Drug User Fee Act target action date is set for October 13, 2025.

Burnett noted the particular treatment challenges in younger populations in an earlier statement

: “AD presents unique challenges in this youngest age group, not only because the skin is more sensitive, but also because the condition often covers a greater percentage of their total body surface area compared to older children and adults. In addition, long-term management of AD requires treatment that can deliver rapid relief of itch, sustained symptom improvement over time, and that is tolerable when applied to the skin.” He added, “Our goal is to address this unmet need by providing advanced targeted topical therapies that can manage symptoms effectively over the long-term, while also improving the quality of life for individuals and their families living with this chronic condition.”

Additionally, the phase 2 INTEGUMENT-INFANT study will evaluate the safety and efficacy of roflumilast in infants aged 3 months to under 2 years.

Atopic dermatitis affects an estimated 16.5 million adults in the US and remains the most common form of eczema. The AAD’s updated recommendations help ensure that treatment decisions reflect the latest safety and efficacy data from real-world use and clinical trials, enabling dermatologists to tailor care to patients' evolving needs.

Arcutis’ ZORYVE® (roflumilast) cream 0.15% receives strong recommendation in American Academy of Dermatology updated guidelines for adult atopic dermatitis. News release. Arcutis Biotherapeutics. June 26, 2025. Accessed June 26, 2025. 

https://www.globenewswire.com/news-release/2025/06/26/3105808/0/en/Arcutis-ZORYVE-roflumilast-Cream-0-15-Receives-Strong-Recommendation-in-American-Academy-of-Dermatology-Updated-Guidelines-for-Adult-Atopic-Dermatitis.html

Davis DMR, Frazer-Green L, Alikhan A, et al. Focused update: guidelines of care for the management of atopic dermatitis in adults. 

 Published online June 17, 2025. doi:10.1016/j.jaad.2025.05.1386

NPF expands seal of recognition to FDA-approved treatments and awards its first to Arcutis’ Zoryve (roflumilast). News release. Arcutis Biotherapeutics. June 2, 2025. Accessed June 26, 2025. 

https://www.arcutis.com/npf-expands-seal-of-recognition-to-fda-approved-treatments-and-awards-its-first-to-arcutis-zoryve-roflumilast/

U.S. FDA accepts supplemental new drug application for Arcutis’ ZORYVE® (roflumilast) cream 0.05% for the treatment of children aged 2 to 5 with mild to moderate atopic dermatitis. News release. Arcutis Biotherapeutics. February 26, 2025. Accessed June 26, 2025. 

https://investors.arcutis.com/news-releases/news-release-details/us-fda-accepts-supplemental-new-drug-application-arcutis-zoryver

Arcutis to present new long-term results of ZORYVE® (roflumilast) cream at the 2025 Revolutionizing Atopic Dermatitis Conference. News release. Arcutis Biotherapeutics. June 6, 2025. Accessed June 26, 2025. 

https://www.globenewswire.com/news-release/2025/06/06/3095048/0/en/Arcutis-to-Present-New-Long-Term-Results-of-ZORYVE-roflumilast-Cream-at-the-2025-Revolutionizing-Atopic-Dermatitis-Conference.html

Hebert A, Eichenfield L, Gonzalez M, et al. INTEGUMENT-INFANT: a phase 2, 4-week, open-label safety study of roflumilast cream 0.05% in infants aged 3 months to less than 2 years with atopic dermatitis. Poster presented at: 2025 Revolutionizing Atopic Dermatitis (RAD) Conference; June 6-7, 2025; Nashville, Tennessee.

Roflumilast 0.15% is the only 1 of 4 newly evaluated branded topical therapies to receive the Academy's strong recommendation for AD management in adults.  

Roflumilast Cream 0.15% Receives Strong Recommendation for Atopic Dermatitis in AAD Guideline Update 

A 5-year-old boy with a history of atopic dermatitis since 6 weeks of age, presents with a rash around his mouth that has been present for approximately 1 year. The patient’s mother reports that desonide topical cream was applied to the affected area for about 5 days, which initially resulted in improvement, however the rash returned after this medication was discontinued. The rash also recently improved after the patient took amoxicillin for an infection. She also notes that the patient has been licking his lips more frequently.

On examination there is an erythematous papulopustular eruption restricted to the perioral region, with sparing of the vermillion border. Mild hyperpigmentation is noted on the patient’s neck. There is no active involvement of other areas of the body.

The eruption has been present for 1 year and is restricted to the perioral region. What is included in your differential? 

Rash Around the Mouth of a 5-year-old Child


These 2 patients presented with a swollen hand and rapidly proximally progressive edema secondary to a bite.

These 2 patients presented with a swollen hand and rapidly proximally progressive edema secondary to a bite. What creature did the biting?

Swollen Hands-What’s Biting?

A 76-year-old woman seeks your attention for an asymptomatic “red spot” on her neck. She has a history of multiple non-melanoma skin cancers.

Squamous cell carcinoma in situ (Bowen  disease)

Lichenoid keratosis (an inflammatory variant of seborrheic keratosis)

A 76-year-old woman seeks your attention for an asymptomatic “red spot” on her neck. What does this look like to you?

Suzanne M. Strowig, MSN, RN

Articles

Latest Updated Articles